Program – Hall B

Thursday, September 5, 2019

06:45-08:00
 Morning Industry Symposium:
New surgical techniques for removing and staging breast cancer
Supported by Endomag
Breakfast will be served prior to the session		 Hall B
Chairpersons    
09:30-10:30 Session 5: Imaging / Screening
 Hall B
Chairpersons Bruce Mann, Australia
Debra Ikeda, USA
09:30 -09:45 MRI screening in women without hereditary risk
Ritse Mann, The Netherlands
09:45-09:55 The implications of a move to MRI screening
Allison Rose, Australia
09:55-10:15 Debate: That women with low risk for breast cancer should only be screened every 3 years
09:55 Yes: Martin Eklund, Sweden
10:05 No: Heather Greenwood, USA
10:15-10:30 Panel discussion:
Martin Eklund, Sweden
Ritse Mann, The Netherlands
Allison Rose, Australia
Heather Greenwood, USA
10:30-11:00 Coffee break and poster viewing  
Chairpersons    
11:00-12:30 Session 7: DCIS Hall B
Chairpersons Hiram S. Cody III, USA
Donna Pinto, USA
11:00-11:35 Debate: That most DCIS should not be a target for screening
11:00 Yes: Laura Esserman, USA
11:10 No: Bruce Mann, Australia
11:20

 Discussion
11:35-12:10 Debate: Most patients with DCIS should not have radiotherapy after Breast Conserving Surgery
11:35 Yes: Alastair Thompson, USA
11:45 No: Thomas A. Buchholz, USA
11:55 Discussion
12:10-12:30 Role of genomic assays in DCIS
Rita Mukhtar, USA
12:30-14:00 Lunch break and poster viewing  
Chairpersons    
12:45-13:45
 Industry Lunch Symposium:
Innovative oral treatment options for patients: HR+/HER2- MBC or gBRCA-Mutated TNBC and HR+/HER2- MBC 
Supported by Pfizer
 Hall B
Chairpersons    
14:00-15:30 Session 9:
Free Papers: Oncoplastic/Imaging*		 Hall B
Chairpersons Mark V. Schaverien, USA
Julia Camps-Herrero, Spain
Stuart McIntosh, UK
14:00-14:10 Making sure no tumor is left behind: Micro-elastography proves an accurate technique to assess tumor margins
Christobel M. Saunders, Australia
14:10-14:20 Temporal trends in the management of women diagnosed with DCIS of the breast in Australia and New Zealand
Rachel Farber, Australia
14:20-14:30 Reduction of margin positivity by Enhanced Intraoperative Breast Specimen Assessment (EISA) to a similar degree as routine Cavity Shave Margins (CSM)
Sami Shoucair, USA
14:30-14:40 Dosimetric planning technique comparison of AeroformTM tissue expanders versus saline tissue expanders in patients ungoing post-mastectomy radiation therapy
Jennie Gilliman, Australia
14:40-14:50 Prepectoral reconstruction with Braxon® ADM mesh
Ahmed Shalaby, UK
14:50-15:00 A simple intervention for long-term relief of chronic post mastectomy pain
Holly Keane, Australia
15:00-15:10 Salvage of the previously un-salvageable peri-prosthetic breast infection after breast reconstruction
Farid Meybodi, Australia
15:10-15:20 Subjective versus objective evaluation of aesthetic outcome after breast surgery
Negin Sedaghat, Australia
15:20-15:30 Outcomes following single-stage pre-pectoral breast reconstruction using implant and acellular dermal matrix: A single-centre experience of 500 reconstructions
Rajiv Dave, UK

* This is a non CME session

15:30-16:00 Coffee break and poster viewing  
Chairpersons    
16:00-17:30 Session 11:
Free Papers: Medical Oncology*		 Hall B
Chairpersons Javier Cortes, Spain
Richard Schwab, USA
Jo Chien, USA
16:00-16:10 Pathological characteristics and treatment outcome of Inflammatory Breast Cancer (IBC) in Egypt:
A multicenter retrospective case series
Aliaa Shamardal, Egypt
16:10-16:20 Efficacy of low dose methotrexate treatment for granulomatous mastitis
Jeffrey Sugandi, USA
16:20-16:30 Utilisation and short-term outcomes of neoadjuvant systemic therapy in breast cancer: A national prospective multi-centre cohort study
Stuart McIntosh, UK
16:30-16:40 The influence of neoadjuvant chemotherapy on the plan for breast-conserving surgery in early or locally advanced breast cancer
Adeline Rankin, UK
16:40-16:50 Electronic data capture in clinical trials: State of play and improvements for the future
Marie Osdoit, France
16:50-17:00 Tumor microenvironment of metastasis (TMEM): A new biomarker and treatment paradigm
Jesus Anampa Mesias, USA
17:00-17:10 Development of a multi-ethnic polygenic risk score for use in a trial of breast cancer screening
Mandy Che, USA
17:10-17:20 The use of 18F-FDG PET/CT as an initial staging procedure for stage II-III breast cancer: A multicenter value analysis
Colby Hyland, USA
17:20-17:30 Disease free survival in node positive Invasive Lobular Carcinoma with or without axillary dissection
Mary Kathryn Abel, USA

* This is a non CME session

17:30-18:30 Poster Session Poster area
Chairpersons    

Friday, September 6, 2019

06:45-08:00
 Morning Industry Symposium:
Identifying the right patients for chemotherapy in ER+ HER2- breast cancer 
Supported by Genomic Health
Breakfast will be served prior to the session		 Hall B
Chairpersons    
08:00-09:30 Session 13: Imaging as locoregional staging Hall B
Chairpersons Alastair Thompson, USA
Allison Rose, Australia
08:00-08:35 Debate: That axillary ultrasound is an essential part of early breast cancer workup
08:20 Yes: Debra M. Ikeda, USA
08:20 No: Hiram S. Cody III, USA
08:20

 Discussion
08:35-09:15 Debate: That contrast imaging should be part of the workup of early breast cancer
08:35 Yes: Christiane Kuhl, Germany
08:45 No: Michael Alvarado, USA
08:55 Discussion
09:15-09:30 Intraoperative imaging
Julia Camps-Herrero, Spain
09:30-10:30 Session 15: Management of impalpable lesions Hall B
Chairpersons Judy C. Boughey, USA
Amit Agrawal, UK
09:30-09:40 Why we need to change
Bruce Mann, Australia
09:40-09:50 The case for Magtrace
Michael Alvarado, USA
09:50-10:00 The case for ICG
Ava Kwong, Hong Kong
10:00-10:10 The case for Seeds
Abigail S. Caudle, USA
10:10-10:20 The case for radar localization (Savi Scout)
Tanya Moseley, USA
10:20-10:30 Discussion
10:30-11:00 Coffee break and poster viewing  
Chairpersons    
12:45-13:45 Industry Lunch Symposium:
HER2-positive early breast cancer:  Determining adjuvant treatment following neoadjuvant therapy
Supported by Genentech		 Hall B
Chairpersons    
13:45-15:15 Session 18: Metastatic Breast Cancer Hall B
Chairpersons Mark Pegram, USA
Alistair Ring, UK
13:45-14:20 Debate: CDK 4/6 inhibitors should be first line therapy for all patients with newly diagnosed HR+ MBC
13:45 Yes: Stephen Chia, Canada
13:55 No: Mariana Chavez MacGregor, USA
14:05 Discussion
14:20-14:40 What is the approach for patients progressing on CDK 4/6 inhibitors?
Angela DeMichele, USA
14:40-15:15 Debate: ctDNA is now the best method to monitor response in patients with metastatic breast cancer
14:40 Yes: Kevin Kalinsky, USA
14:50 No: Antonio Llombart, Spain
15:00 Discussion
Skip to content